Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Más filtros

Bases de datos
Tipo del documento
Intervalo de año de publicación
1.
Int J Lepr Other Mycobact Dis ; 61(3): 406-14, 1993 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-8228439

RESUMEN

Twenty-five compounds structurally related to clofazimine were tested for their ability to inhibit the growth of Mycobacterium leprae using the kinetic method of drug evaluation in the mouse foot pad model of leprosy. Seven of the phenazine derivatives displayed anti-M. leprae activity comparable to that of clofazimine when administered at a concentration of 0.01% (w/w) in the diet. Three of the compounds, B746, B4087, and B4101, were active when administered at 0.001% in the diet. At a dietary concentration of 0.0001%, B4087 and B4101 were slightly more active than clofazimine, while B746 was less active. In the kinetic method of drug evaluation, greater anti-M. leprae activity of phenazine derivatives was generally associated with greater pigmentation of abdominal fat. Of the compounds which did not cause pigmentation when fed at a concentration of 0.01% in the diet B4090 was the most active. This compound also inhibits the growth of a clofazimine-resistant M. smegmatis strain.


Asunto(s)
Lepra/tratamiento farmacológico , Mycobacterium leprae/efectos de los fármacos , Fenazinas/farmacología , Abdomen , Tejido Adiposo/efectos de los fármacos , Animales , Clofazimina/química , Clofazimina/farmacología , Clofazimina/uso terapéutico , Modelos Animales de Enfermedad , Evaluación Preclínica de Medicamentos , Femenino , Humanos , Cinética , Lepra/microbiología , Ratones , Estructura Molecular , Mycobacterium leprae/crecimiento & desarrollo , Fenazinas/química , Fenazinas/uso terapéutico , Pigmentación
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA